A year of successful cancer vaccines points to a path forward

Michael A Morse; Michael Whelan

A year of successful cancer vaccines points to a path forward

Curr Opin Mol Ther. 2010 Feb;12(1):11-3.

Authors

Michael A Morse¹, Michael Whelan

Affiliation

¹ Duke University Medical Center, Durham, NC 27710, USA. morse004@mc.duke.edu

PMID: 20140811

Abstract

Results from recent clinical trials of the therapeutic vaccines sipuleucel-T (Dendreon Corp), PROSTVAC-VF-TRICOM (National Cancer Institute/BN ImmunoTherapeutics Inc) and BiovaxID (Biovest International Inc) are highlighted. These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer.

Publication types

Review

MeSH terms

Cancer Vaccines / therapeutic use*
Clinical Trials as Topic
Humans
Male
National Cancer Institute (U.S.)
Neoplasms / drug therapy*
Neoplasms / immunology
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / prevention & control
United States

Substances

Cancer Vaccines